Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TH 0059

Drug Profile

TH 0059

Alternative Names: HSB-0059; TH-0059

Latest Information Update: 23 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tharimmune
  • Class Antineoplastics; Bispecific antibodies; Immunoconjugates; Immunotoxins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 17 Jan 2024 Preclinical trials in Cancer in USA (Parenteral) (Tharimmune Pipeline, January 2024)
  • 17 Jan 2024 Tharimmune plans IND-enabling studies in Cancer in USA in 2025 (Tharimmune Pipeline, January 2024)
  • 13 Feb 2023 Hillstream Biopharma enters into an exclusive option agreement with Applied Biomedical Science Institute to license HER2 and HER3 Conformational Domain Bridging Epitopes technology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top